|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0009324,
umls-concept:C0030705,
umls-concept:C0231199,
umls-concept:C0332152,
umls-concept:C0332257,
umls-concept:C0666743,
umls-concept:C0871261,
umls-concept:C1122087,
umls-concept:C1517945,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C2603343,
umls-concept:C2911692
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
2009-8-26
|
|
pubmed:abstractText |
The aim of this study was to assess the clinical benefit and tolerability of adalimumab, a fully human monoclonal antibody to tumor necrosis factor (TNF), in patients with ulcerative colitis (UC).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
1536-4844
|
|
pubmed:author |
pubmed-author:AfifWaqqasW,
pubmed-author:BruiningDavid HDH,
pubmed-author:CohenRussell DRD,
pubmed-author:FaubionWilliam AWA,
pubmed-author:HanauerStephen BSB,
pubmed-author:HansonKaren AKA,
pubmed-author:KaneSunanda VSV,
pubmed-author:LeightonJonathan AJA,
pubmed-author:LoftusEdward VEVJr,
pubmed-author:PardiDarrell SDS,
pubmed-author:RubinDavid TDT,
pubmed-author:SandbornWilliam JWJ,
pubmed-author:TremaineWilliam JWJ
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
15
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1302-7
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:19408340-Adult,
pubmed-meshheading:19408340-Aged,
pubmed-meshheading:19408340-Anti-Inflammatory Agents,
pubmed-meshheading:19408340-Antibodies, Monoclonal,
pubmed-meshheading:19408340-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:19408340-Colitis, Ulcerative,
pubmed-meshheading:19408340-Female,
pubmed-meshheading:19408340-Follow-Up Studies,
pubmed-meshheading:19408340-Humans,
pubmed-meshheading:19408340-Male,
pubmed-meshheading:19408340-Middle Aged,
pubmed-meshheading:19408340-Prognosis,
pubmed-meshheading:19408340-Salvage Therapy,
pubmed-meshheading:19408340-Treatment Outcome
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab.
|
|
pubmed:affiliation |
Miles & Shirley Fiterman Center for Digestive Diseases, Mayo Clinic, Rochester, MN 55905, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II
|
